Liquid Biopsies Congress

When

2019年10月10-11日
Registration from 8am

Where

英国,伦敦
London Heathrow Marriott Hotel

Liquid Biopsies Congress
-液体活检学会-
日期:2019年10月10-11日
地点:英国,伦敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Liquid Biopsies Congress

探索液体活检在诊断,预测和治疗上的应用

了解专家如何利用qPCR,数位PCR和次世代定序 (NGS)等技术加速液体活检──这个癌症非侵入性诊断的发展。这次学会将以循环生物标志物,如无细胞DNA、(cfDNA)、循环肿瘤细胞(CTC)和细胞外囊泡(EV)为焦点。

“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.

“Interesting mixture of topics; possibility to discuss with the attendees”

“Learned a lot from some of the talks”

2019年10月10日(四) – LIQUID BIOPSIES; TECHNIQUES AND TECHNOLOGIES


Keynote Address: A universal biomarker for cancer: Are we there yet?
MATT TRAU, Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia
Epigenetic reprogramming in cancer genomes creates a distinct methylation landscape encompassing clustered methylation at regulatory regions separated by large intergenic tracks of hypomethylated regions. This methylation landscape that we referred to as Methylscape is displayed by most cancer types, thus may serve as a universal cancer biomarker. We examine the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. We find that DNA polymeric behaviour is strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. We exploit these Methylscape differences to develop simple, highly sensitive and selective electrochemical or colorimetric one-step assays for the detection of cancer. These assays are quick, i.e., analysis time≤10minutes, and require minimal sample preparation and small DNA input from either solid or liquid biopsies.

Keynote Address: Enabling Liquid Biopsy in Cancer and Beyond
SIMON LUCAS, Innovation Field Explorer, Merck KGaA
The early detection of life-threatening conditions as well as the selection of individualized treatment options for affected patients will have significant potential to disrupt our current public health sectors. Recently, alternatives to traditional tissue biopsy, such as liquid or breath biopsy, have emerged as attractive tools for the detection and management of various diseases and especially in the therapeutic area of oncology. While cancer detection with liquid biopsy is gaining acceptance, other indications often still lack a non-invasive diagnostic test, even though precision medicine is viewed as an important concept in indications outside oncology. This talk highlights the opportunities of liquid biopsy in cancer and beyond as well as our efforts at Merck to address challenges in the field with new enabling technologies.

PRESENTATION


Morning Refreshments / Poster Presentations / One-to-One Meetings


Considerations when analyzing cell-free tumor DNA
ANDERS STAHLBERG, Associate Professor, University of Gothenburg, Sweden
• Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA.
• We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input.
• Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.

Standardized analysis of extracellcular vesicles in liquid biopsies
AN HENDRIX, Assistant Professor, University of Ghent, Belgium
The identification of extracellular vesicle (EV)-associated biomarkers is challenging owing to the complexity of liquid biopsies. We 1) performed quality control studies to identify the impact of (pre-) analytical variables on biomarker identification, 2) developed reference materials to ensure standardized EV measurements, and 3) created EV-TRACK to stimulate researchers to put experimental guidelines into practice. This combined expertise boosted the identification of bacterial EV in the systemic circulation of patients with intestinal barrier dysfunction.

PRESENTATION


Lunch


Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events
DOLORES CAHILL, Professor of Translational Science, University College Dublin, Ireland
Overview of profiling the autoantibody repertoire on high content protein arrays and using this approach to identify biomarkers, and develop diagnostics and companion diagnostics.

Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer
JEAN-YVES PIERGA, Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Universite Paris Descartes, France
Circulating tumor cells (CTCs) have been identified as potential blood-based biomarker capable of providing prognostic and predictive information in breast cancer. Their applications include early diagnosis, prognostic assessment, detection of minimal residual disease, early detection of cancer relapse and management of metastatic disease. The clinical validity of the CTCbased liquid biopsy has been already assessed by numerous studies. Pooled analysis of large clinical data set in adjuvant, neoadjuvant and metastatic setting are now available. Recent results of clinical trial could support their clinical utility. The potential applications for circulating tumour DNA (ctDNA) in early and metastatic setting include prognosis assessment before treatment initiation, early assessment of treatment efficacy and help to guide personalized therapies.

PRESENTATION
ROBERT NEELY (Reserved), Associate Director, Pharmacodiagnostics, BMS


Afternoon Refreshments / Poster Presentations / One-to-One Meetings


Translating liquid biopsies into routine care
PANEL DISCUSSION – Speakers include:

KATARZYNA WITKOWSKA
Commercial Partnerships Manager, Genomics England, UK

KAREN SPINK
Innovation Lead - Precision Medicine, Innovate UK
ALEXANDRE HARLE
Assistant Professor, Molecular Biologist, Institut de Cancerologie de Lorraine, France
IWANKA KOZAREWA
Senior Scientist, AstraZeneca, UK
BERNHARD POLZER
Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for
Toxicology and Experimental Medicine ITEM-R, Germany
SIMON LUCAS
Innovation Field Explorer, Merck KGaA, Germany


Networking Drinks Reception


2019年10月11日(五) - CLINICAL APPLICATIONS

Keynote Address: A Liquid Biopsy Assay to detect Cancer
DIANA ANDERSON, Established Chair, Biomedical Sciences, University of Bradford, UK
There appeared to be no single test to identify cancer in general, but we have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes from blood of 208 individuals, known as the Lymphocyte Genome Sensitivity (LGS) test. Ninety four individuals were controls. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic (ROC) curves, of mean log Olive tail moments for cancer alone versus controls alone, the area under the curve was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable
complementary measures. Since lymphocytes in blood only are examined, and the test has been repeated with over 900 individuals with equally valid responses, this is a useful Liquid Biopsy assay.

Liquid biopsies on the road to clinical utility
RALPH GRAESER, Senior Translational Medicine Expert, Boehringer Ingelheim
• Use of liquid biopsies in the clinic: diagnostic, prognostic, predictive?
• CTCs vs ctDNA: one or the other - or both?
• CANCER-id - a public-private partnership with the goal to standardize liquid biopsy protocols for clinical use


Morning Refreshments / Poster Presentations / One-to-One Meetings


Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
MIKE MAKRIGIORGOS, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis. Application in circulating DNA from clinical cancer samples will be presented.

A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers
JOHN MARTIGNETTIProfessor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA
Overwhelmingly the power and success of “liquid biopsy” has been focused on issues related to advanced disease in already diagnosed patients under active treatment. We demonstrate an approach and the feasibility of using a targeted liquid biopsy approach for detecting early stage gynecologic cancers by combining analysis of both DNA and proteins.


Lunch


CTC analysis: Latest advancements and clinical applications
EVI LIANIDOU, Professor of Analytical Chemistry - Clinical Chemistry, University of Athens, Greece
• Liquid biopsy provides a valuable source of biomarkers through simple and minimally invasive serial blood draws and represents a highly dynamic diagnostic, prognostic and theranostic tool for the management of cancer patients.
• Circulating tumor cells (CTCs) are major players in liquid biopsy and their molecular characterization offers
an exciting approach to monitor the efficacy of systemic therapies in real-time, unravel the biology of cancer cell dissemination, understand resistance to established therapies and identify gene targets and signalling pathways relevant to therapeutic interventions.
• Single-cell CTC analysis is a powerful tool to understand tumor heterogeneity and the mechanisms involved in cancer progression with potential implications for improving treatment strategies.
• This lecture will be focused on the latest developments in the detection and molecular characterization of CTCs, and their clinical applications in many types of cancer.

Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib
LUDOVIC BARAULT, Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy
• Regorafenib is associated with improved progression free survival (PFS) in a subset of metastatic colorectal cancer
(mCRC) patients and no biomarkers of efficacy are available for this drug which is often associated with many toxicities.
• We previously found an association between circulating methylated DNA and outcome in chemotherapy treated mCRC patients and we hypothesized that such biomarker could be used to identify cases most likely to benefit from regorafenib (i.e. patients with PFS longer than 4 months).
• Assessment of pre and on treatment blood samples confirmed the prognostic value of circulating methylated DNA and suggest its use as biomarker for regorafenib since it may predict unresponsiveness to the treatment.

PRESENTATION
ANDREAS HAUSER, Staff Scientist, LMU, Germany


Chair’s Closing Remarks / Conference Close


 

* 活动内容有可能不事先告知作更动及调整。

演讲者

议程

由于这个学会针对的是正在努力创造可以加快疾病检测,早期诊断,加强疾病监测和治疗反应的低侵入性活检技术的研究人士,届时预计将吸引350以上该领域的专家。

Download the Agenda (PDF)

赞助商

所有赞助商名单

地点

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海报发表

海报发表除了在休息时间之外,更与分组会议单元同时进行。制药公司和研究机关的研究人员制所作的海报,会在通过学会审核之后,于会场内指定区域展示。

我们还会向所有与会者发放海报电子书,如果您愿意,可以在会议结束后以PDF格式分享您的海报(可自由选择)。

无论是寻找资金,就业机会还是只是想与志同道合,专心致力的研究团队分享您的工作成果,会场内的海报都是让您吸引众人注目的宝贵机会。

参加海报发表,您需要先报名登记参加学会。海报展示空间有限,将依报名顺序加以审核,恳请提早报名以免向隅。

我们向行业代表收取100英镑的管理费,用于提供海报展示区和展板,指南等共同费用。代表学术机构而非营利组织的人则免收这笔费用。

海报发表的申请方法

请填写专用表格 (下列链接可下载) ,在2019年9月20日前提交。但因空间有限,敬请早日申请以免向隅,如有任何问题请洽询联络处。

学会的赞助商

募集赞助商

成为这个学会的赞助商或参展商,您可在融洽的气氛中,一面和专家们交流彼此的意见,同时也有机会和各种组织代表进行官方或非官方会谈,以建立彼此的合作关系。

此外我们更准备了各种赞助商配套方案,您可考量自身的预算及业务需求,选择能让您获得最大投资收益的方案。

如果您有除此之外,成为赞助商来开展您宣传活动的其他建议,也欢迎您随时与我们连络,我们将配合您的需求提供各种提案。

可事前预约的二十分钟一对一个别会谈

在主要会议议程的分组会议期间将举行一系列事先预约的二十分钟个别会谈,选择您想要会见的代表。在会议期间Global Engage的团队将随时待命,确保您的所有会议按时举行。

主要会议前后的研讨会

在主要会议前后,将举办为了对特定主题有兴趣的与会者所办的全天或半天研讨会。Global Engage将协助您在研讨会上进行宣传活动,并确保够多人出席。

学会开幕前的行销和品牌宣传

您也可利用Global Engage的资料库来进行行销,更可揭示海报,成为休息和午餐会、招待会、海报单元的赞助商来提升您的品牌知名度。此外我们也另外提供可在发给与会者的挂绳,和学会资料袋上印刷标志以提升品牌知名度的选项。

参展

会期中,您可在会场内所设的专用区向所有的与会者发表您的技术及产品。展会区同时也是休息及午餐会,第一天傍晚举行的招待会的会场。

演讲

演讲的形态

  • 30分钟的演讲
  • 以主持人或小组成员身分参加30分钟专题研讨会
  • 在学会的议程中召开1小时的研讨会
募集赞助商

详细内容请洽询GII联络处。

包括签证等各种海关所需文件,以及展示用品的通关手续皆由展商企业各自负责。

展示相关的安排(企业介绍、公司商标、提供与会者目录中的展商资讯登录、展示空间的装潢、用品订购、展示用品的摆设搬运、展示空间的文件申请、保险等)请直接与主办方连系。

旅游相关疑问(住宿、机票)、当地翻译人员、飞行与意外保险等问题,将有另外的专门业者分别提供服务。

Liquid Biopsies Congress的赞助商相关详情请洽询联络处。

关于与会者、配套方案、新募集情报等详细资讯,请洽询联络处。我们将竭诚为您提供关于您评估这场活动所需的所有资讯。

媒体合作伙伴

  • 247 Updates
  • Biocompare
  • Bentham Science
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免费电子邮件通知服务